InvestorsHub Logo
Followers 27
Posts 5124
Boards Moderated 0
Alias Born 01/27/2014

Re: None

Monday, 06/15/2020 10:02:34 AM

Monday, June 15, 2020 10:02:34 AM

Post# of 30393
Seelos Therapeutics to Host Key Opinion Leader Call to Discuss Phase I Data and Upcoming Trial Design for SLS-002

Source: GlobeNewswire Inc.

Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to provide updates regarding data from the Phase I study of SLS-002 on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. Seelos will also provide an overview of the design for Seelos’ next study of SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD) during the call.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SEEL News